Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum: Evaluation of the Safety and Effectiveness of Ciltacabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma: Findings from a CIBMTR Study

  • By

  • Doris K. Hansen

  • Danai Dima

  • Hira Mian

  • Jakob Devos

  • Ruta Brazauskas

  • Temitope Oloyede

  • Aimaz Afrough

  • Nausheen Ahmed

  • Larry D. Anderson

  • Rahul Banerjee

  • Jesus G. Berdeja

  • Aram Bidikian

  • Binod Dhakal

  • Ajoy Dias

  • Yvonne Efebera

  • Muhammad Salman Faisal

  • Lohith Gowda

  • Hamza Hashmi

  • Abu-Sayeef Mirza

  • Meera Mohan

  • Ravi Narra

  • Ashley E. Rosko

  • Mark Schroeder

  • Taiga Nishihori

  • Heather Landau

  • Saad Usmani

  • Marcelo C. Pasquini

  • Othman S. Akhtar

  • Surbhi Sidana

  • Krina K. Patel

  • August 31, 2026

Share

Clinical Scorecard: Erratum: Evaluation of the Safety and Effectiveness of Ciltacabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma: Findings from a CIBMTR Study

At a Glance

CategoryDetail
ConditionRelapsed/Refractory Multiple Myeloma
Key MechanismsCiltacabtagene Autoleucel is a CAR T-cell therapy targeting BCMA.
Target PopulationPatients with relapsed/refractory multiple myeloma.
Care SettingClinical oncology settings.

Key Highlights

  • Correction of author's name in published article.
  • Ciltacabtagene Autoleucel evaluated for safety and effectiveness.
  • Findings derived from a CIBMTR study.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients with relapsed/refractory multiple myeloma.

          Ciltacabtagene Autoleucel is utilized in this patient population.

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study

            • by Doris K. Hansen, Danai Dima, Hira Mian, Jakob Devos, Ruta Brazauskas, Temitope Oloyede, Aimaz Afrough, Nausheen Ahmed, Larry D. Anderson, Rahul Banerjee, Jesus G. Berdeja, Aram Bidikian, Binod Dhakal, Ajoy Dias, Yvonne Efebera, Muhammad Salman Faisal, Lohith Gowda, Hamza Hashmi, Abu-Sayeef Mirza, Meera Mohan, Ravi Narra, Ashley E. Rosko, Mark Schroeder, Taiga Nishihori, Heather Landau, Saad Usmani, Marcelo C. Pasquini, Othman S. Akhtar, Surbhi Sidana, Krina K. Patel

            • August 31, 2026

            Related Content

            Molecular Diagnostics Go Mobile

            A smartphone-linked fluorimeter detects infectious disease and cancer biomarkers in 10-minute assays

            • August 31, 2026

            • 3 min
            Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget’s disease with bone marrow involvement: a case report

            This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

            A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

            • August 31, 2026

            • 5 min